[1] BARON R.Osteoporosis in 2011:Osteoporosis therapy-dawn of the post-bisphosphonate era[J].Nat Rev Endocrinol,2012,8(2):76.
[2] 林华,陈新,张咏梅,等.绝经后骨质疏松骨量与血脂利塞膦酸钠干预的研究[J].中国骨质疏松杂志,2009,15(8):590.
[3] 钱云峰,孙伟珊,魏秋实,等.福美加对去势骨质疏松大鼠血脂代谢指标的影响[J].华南国防医学杂志,2013,27(6):376.
[4] RESZKA AA,RODAN GA.Bisphosphonate mechanism of action[J].Curr Mol Med,2002,5(1):571.
[5] SAMELSON EJ,CUPPLES LA,HANNAN MT,et al.Longterm effects of serum cholesterol on bone mineral density in women and men:The Framingham Osteoporosis Study[J].Bone,2004,34(3):557.
[6] SIVAS F,ALEMDAROĞ LU E,EL VERICI E,et al.Serum lipid profile:its relationship with osteoporotic vertebrae fractures and bone mineral density in Turkish postmenopausal women[J].Rheumatol Int,2009,29(8):885.
[7] BROWNHILL RA,LLICH JZ.Lipid profile and bone paradox:higher serum lipids are associated with higher bone mineral density in postmenopausal women[J].Women's Health,2006,15(3):261.
[8] OROZCO P.Atherogenic lipid profile and elevated lipoprotein(a) are associated with lower bone mineral density in early postmenopausal overweight women[J].Eur J Epidemiol,2004,19(12):1105.
[9] 李跃华,薛李,赵芳芳,等.原发性骨质疏松症中医证型分布及其与骨折关系研究[J].中国中西医结合杂志,2010,30(5):493.
[10] 史晓,蔡奇文,杜修东,等.原发性骨质疏松症病人中医量表的信度及效度研究[J].中医杂志,2009,15(2):124.